Sökning: onr:"swepub:oai:DiVA.org:uu-194739" >
Cytoreductive treat...
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study
-
Besses, Carlos (författare)
-
Kiladjian, Jean-Jacques (författare)
-
Griesshammer, Martin (författare)
-
visa fler...
-
Gugliotta, Luigi (författare)
-
Harrison, Claire (författare)
-
Coll, Ruth (författare)
-
Smith, Jonathan (författare)
-
Abhyankar, Brihad (författare)
-
- Birgegård, Gunnar (författare)
- Uppsala universitet,Hematologi
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- Engelska.
-
Ingår i: Leukemia Research. - : Elsevier BV. - 0145-2126 .- 1873-5835. ; 37:2, s. 162-168
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- EXELS is an ongoing phase IV non-interventional study; 3643 high-risk patients with essential thrombocythemia (ET) were recruited across 13 European countries. We report patient characteristics and cytoreductive treatment patterns of ET across Europe. Hydroxycarbamide (HC; 64.3%) and anagrelide (22.0%) were the two main cytoreductive treatments prescribed. The proportions of patients taking either HC or anagrelide varied across countries, as did the number of patients receiving anti-aggregatory therapy in addition to cytoreductive treatment. This real-world evidence demonstrates that, generally, treatment patterns of ET across Europe adhere to expert recommendations, with some notable variations between countries.
Nyckelord
- Essential thrombocythemia
- Cytoreductive treatment
- Anagrelide
- Hydroxycarbamide
- Interferon
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas